Good luck with the Perispinal Etanercept because the previous proponent was never willing to do the hard work of clinical research on it.
Dr. Tobinick(21 posts) seems to have never even entertained trying to get his uses of etanercept tested in a clinical trial.
This is probably what etanercept is supposed to address.
Inhibition of Tnf-α R1 signaling can rescue functional cortical plasticity impaired in early post-stroke period
Return to Life Return to Work research grants announced - Australia
Australia’s working age stroke survivors are set to benefit from research into innovative recovery and rehabilitation clinical interventions.Stroke Foundation today announced the recipients of the $1 million ‘Return to life, return to work’ clinical research grants for 2019.
Funded by the Federal Government through the Medical Research Future Fund, the research package includes Australia’s first multicentred clinical trial of Perispinal Etanercept in chronic stroke.
Stroke Foundation Research Advisory Committee Chair Professor Amanda Thrift said the grants were an investment into the future of Australia’s younger stroke survivors.
“Around 142,500 Australian stroke survivors are of working age. International evidence shows incidence of stroke among young people is increasing, so we must do more to ensure tailored services and supports are available,” Professor Thrift said.
“Stroke strikes the brain and can leave a lasting impact on independence, family life, finances and careers – particularly for those in their 20s to 50s.
“While advancements in acute stroke treatment mean more Australians are surviving than ever before, recovery can be a long and challenging journey physically, cognitively and mentally.
“This funding package has the potential to provide break-through treatments to those suffering from the impact of stroke allowing them to optimise their recovery and return to the things in life which fulfil them most,” she said.
Grant recipients:
Professor Vincent Thijs, Florey Institute of Neuroscience and Mental Health
Perispinal Etanercept to improve Stroke Outcomes (PESTO)
Seeks to determine if Perispinal Etanercept improves quality of life in working age patients who have a history of stroke and moderate to severe disability. It will also investigate if repeated treatments lead to improved quality of life compared to one treatment.
Associate Professor Natasha Lannin, School of Allied Health, Latrobe University, Alfred Health
Does an embedded vocational rehabilitation intervention improve employment outcomes above and beyond standard stroke rehabilitation?
The grant will fund a pilot project to test the feasibility and potential benefit of building on current clinical rehabilitation by adding an embedded 12 week targeted vocational rehabilitation.
/Public Release. View in full here.
Hey there,
ReplyDeleteA bit unfair to target Tobinick (the Floridian dermatologist who pioneered perispinal etanercept for stroke). It was the NEUROLOGISTS who should have done this research, as they are the ones with the expertise. Instead, they poo-poohed his work for many years. Then, after some lobbying in Australia, presto! A grant! Research!
You are pretty right with your blurb; the key is pretty complex though. It is best to look at all strokes (after stabilisation) as "immune response" strokes. It is the immune response (with CD14 as the main culprit) which is the on-going enemy.
There is some really wonderful research going on though. Everything suggests that drugs like fasudil and IC14 will be the solution. The right (tailored) dose to reduce CD14 levels will alleviate symptoms very, very substantially. Way beyond even the best results etanercept has ever achieved.